Stock Ratings / Health Care / PRAX / financials

ABVX (54) KNSA (71) ALKS (79) ARWR (59) ⌘ Pro Terminal →

Praxis Precision Medicines Inc. (PRAX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$288.62 +1.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Praxis Precision Medicines Inc. (PRAX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $8.06B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRAX)Realized 20D OHLCV Swing Band: ±9.6%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PRAX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.4M

FY24

Rev $8.6M

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	0%	-8.2%	-$303.0M	-$249.1M	-45%
FY 2024	$8.6M	52%	-2340.3%	-$183.0M	-$131.8M	-45%
FY 2023	$2.4M	52%	-5164.4%	-$123.0M	-$111.2M	-3.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRAX)

✓Walkthrough of PRAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.51%📐 HORIZONTAL RANGE

2026-11-01O $285.5H $288.6L $285.5C $288.6VOL 508.6K

RES: $415.3SUP: $224.5SMA50: $299.5SMA200: $314.8

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRAX Butterfly Map → + Track PRAX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.5%/yr Implied 5Y Growth

vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRAX)

Health Care Rank #155 of 188 ⚔️ ABVX vs PRAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRAX vs. ABVX, KNSA, ALKS, ARWR)

Industry: Biotechnology: Pharmaceutical Preparations (64 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Praxis Precision Medicines Inc. (PRAX) ranks #155 by composite RQD confidence (48/100, grade D) and #126 by equity capitalization ($8.06B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while ALKS leads on capital efficiency and profitability with 14.0% ROIC and 86.7% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with PRAX at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRAX ACTIVE Praxis Precision Medicines Inc.	D	48/100	—	—	-35.0%	+1.10%	$8.06B	Benchmark Subject
ABVX Abivax SA	D+	54/100	32.8x	—	9.9%	-0.87%	$7.77B	/abvx-vs-prax →
KNSA Kiniksa Pharmaceuticals International plc (Class A)	B-	71/100	129.9x	88.5%	9.9%	+2.50%	$7.67B	/knsa-vs-prax →
ALKS Alkermes plc	B+	79/100	31.5x	86.7%	14.0%	+0.27%	$7.61B	/alks-vs-prax →
ARWR Arrowhead Pharmaceuticals Inc.	C-	59/100	—	—	11.1%	+0.47%	$8.54B	/arwr-vs-prax →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001689548

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Praxis Precision Medicines Inc. (PRAX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $8.6M , and -100.0% cumulative change since FY2023) , GAAP net income of -$303.0M, operating cash flow of -$249.1M, and free cash flow of -$249.1M (-89.1% YoY). On the balance sheet, PRAX closed FY2025 with $937.9M in total assets against $26.9M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$303.0M	-$249.1M	-$249.1M	$937.9M	$26.9M
FY2024 (FY)	2024-12-31	$8.6M	-$183.0M	-$131.8M	-$131.8M	$483.1M	$16.9M
FY2023 (FY)	2023-12-31	$2.4M	-$123.0M	-$111.1M	-$111.2M	$4.43B	$1.04B

3. PRAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Praxis Precision Medicines Inc. (NASDAQ: PRAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $288.62 (+1.10% 1D, market cap $8.06B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 188 tracked Health Care issuers, PRAX ranks #155 in composite RQD confidence.

How does PRAX compare to ABVX and KNSA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRAX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ABVX (Abivax SA) holds a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.77B) and KNSA (Kiniksa Pharmaceuticals International plc (Class A)) posts a B- grade (71/100 RQD, P/E 129.9x, ROIC 9.9%, cap $7.67B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while ALKS leads on capital efficiency (14.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRAX?

Per PRAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001689548), Praxis Precision Medicines Inc. generated $0 in revenue (-100.0% YoY), -$303.0M in net income, and -$249.1M in free cash flow against $937.9M in total assets and $26.9M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRAX trading relative to its 50-day, 200-day, and 52-week technical levels?

PRAX last traded at $288.62 (+1.10% on volume of 508,597 shares), positioning the stock -3.65% below its 50-day simple moving average ($299.54) and -8.31% below its 200-day simple moving average ($314.79). Across its 52-week range of $154.45 to $392.70, PRAX sits at the 56.3% percentile with a 14-day RSI of 56.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.6% ($260.91 to $316.33).

PRAX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Praxis Precision Medicines Inc. (PRAX)?

In FY 2025 (10-K), PRAX converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: PRAX RQD Cockpit PRAX 12M Forecast PRAX Earnings & Move PRAX Dividends & DRIP PRAX Insiders & 13F PRAX Whale Options PRAX Profit Sankey PRAX News & Why